Discover what Emgality can do for patients with chronic migraine1
For your patients with ≥15 headache days per month,1

Meet a patient with chronic migrainea
CLINICAL FACTORS
- 15 or more unpredictable headache days per month
- Has tried therapeutic doses of 2 standard-of care generic preventives
- May now be only relying on her acute treatments
aHypothetical patient profile.
SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

“Having chronic migraine means that at least half my month will be headache days. I need a preventive treatment so I can try to be with my family as much as possible.”
— Hypothetical patient with chronic migraine
Review study design for REGAIN
Review safety profile or the results from the 12-month, open-label safety study for Emgality
References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0120. 3. Data on File. Lilly USA, LLC. DOF-GZ-US-0002. 4. Data on File. Lilly USA, LLC. DOF-GZ-US-0149. 5. Data on File. Lilly USA, LLC. DOF-GZ-US-0063. 6. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. Neurology. 2012;78:1337-1345. 7. Data on File. Lilly USA, LLC. DOF-GZ-US-0057. 8. Data on File. Lilly USA, LLC. DOF-GZ-US-0024. 9. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. 10. Bagley CL, Rendas-Baum R, Maglinte GA, et al. Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52:409-421.